Vergenix™ Flowable Gel (FG) is a recombinant human collagen matrix for
optimal wound management, charting a new course in the treatment of
acute and chronic wounds

Vergenix™FG Physician Testimonial by Prof. Alberto Piaggesi, Director of Diabetic Foot Section, University of Pisa

Vergenix™FG is an innovative bio-degradable wound care device that provides a scaffold for cellular proliferation and capillary growth. It is comprised of a recombinant type I human collagen (rhCollagen) derived from bioengineered tobacco plants and human collagen. A single application of Vergenix™FG provides an optimized treatment for wound healing.

Vergenix™FG is supplied as a lyophilized material contained in a syringe, forming a gel upon hydration with saline.


Vergenix™FG is indicated for the management of acute and chronic wounds, including:

  Full thickness and partial thickness wounds
  Pressure ulcers
  Venous ulcers
  Ulcers caused by mixed vascular etiologies
  Diabetic ulcers
  Second degree burns
  Donor sites and other surface bleeding wounds
  Trauma wounds healing by secondary intention
  Surgical wounds
  Deep and tunneled-undermined wounds


To date, collagen has been extracted from animal and human cadaver sources, baring risk of contamination, allergenicity and impeded biofunctionality due to harsh purification conditions.

Vergenix™FG is made of the first commercially available recombinant human collagen (rhCollagen) produced in plants.
Following introduction of human genes for collagen into tobacco plants, the plant platform effectively expresses fully functional type I human procollagen. The bio-engineered plants are grown, leaves are harvested and procollagen is extracted from the leaves and converted into mature type I rhCollagen.

This technology allows for production of a perfectly structured collagen with undamaged binding sites and nonimmunogenic properties, demonstrating a profile of native human collagen.

Few cell binding domains due to collagen partial structure loss

Many cell binding domains that enhance cellular attachment


Vergenix™FG, made of type I rhCollagen and hydroxypropyl methyl cellulose (HPMC), drives the formation of granulation tissue, one of the most important steps leading to an effective wound closure.

The native and structurally intact form unique to rhCollagen, together with the gel formulation that allows for complete coverage of deep and irregularly shaped wound beds, facilitate wound closure and expedite healing.

Mechanism of action:
  1. Application of Vergenix™FG

    Intimate contact between Vergenix™FG and the surrounding tissue is established.

  2. Cell adhesion and cell proliferation on the scaffold

    The collagen is a natural scaffold for the adhesion and proliferation of cells involved in the wound healing process. Once these cells attach and proliferate, they secrete the natural extracellular matrix (ECM).

  3. Formation of natural extracellular matrix and collagen biodegradation 

    In coordination with the formation of the natural ECM, the collagen from the Vergenix™FG gel starts to degrade as part of the natural turnover of collagen in the body. The new ECM initiates regeneration of the damaged tissue. 

  4. Recruitment of additional cells needed for wound healing

    The peptides resulting from the enzymatic degradation of collagen help recruit additional cells to the wound site, enhancing the wound healing process.

  5. Wound closure


Identical to type I collagen produced by the human body

3-dimensional scaffold for complete wound coverage of hard-to-reach sites in deep and irregularly-shaped wounds

Promotes new tissue formation by recruiting the body’s own healing components for rapid and efficient tissue regeneration

A single application is sufficient, reducing treatment time and easing the burden on patients

Non immunogenic, eliminating the risk of allergic response and exposure to animal pathogens, providing safer wound care

Accelerated cell proliferation which results in faster wound healing, reduced risk of infection and significant clinical improvement in hard-to-treat cases

Skip to toolbar